Fluidigm Targets $48.7M in Net Proceeds from Public Offering

Aug 16, 2012

|

NEW YORK (GenomeWeb News) – Fluidigm today announced a public offering of its shares that is expected to raise $48.7 million in net proceeds.

The South San Francisco, Calif.-based firm is offering 3,660,000 shares of its common stock at $14.25 per share. The offering is expected to close on or about Aug. 21, and proceeds will go toward R&D, commercialization of its products, working capital, and other general corporate use, Fluidigm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Testing Less Likely

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three for Immunotherapy

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

Cancer-Fighting Zombies

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.

This Week in Genome Research

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.